Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment

Hypertension

Volumn 49, Issue 3, 2007, Pages 506-510

  Neumann, Jutta ^a   Ligtenberg, Gerry ^a   Klein, Inge H T ^a   Boer, Peter ^a   Oey, P Liam ^a   Koomans, Hein A ^a   Blankestijn, Peter J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

ACE inhibition; Angiotensin II receptor blocker; Chronic kidney disease; Muscle sympathetic nerve activity; Renal hypertension; Sympathetic hyperactivity

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; LOSARTAN; RENIN;

ADRENERGIC SYSTEM; ADULT; AGE DISTRIBUTION; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTIPLE REGRESSION; MUSCLE CONTRACTION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPATHETIC NERVE; SYMPATHETIC TONE;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; MIDDLE AGED; MUSCLES; SYMPATHETIC NERVOUS SYSTEM;

EID: 33847040428     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000256530.39695.a3     Document Type: Article

References (23)

1. Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease. Nephrol Dial Transplant. 2004;19:1354-1357.
2. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension. 2004;43:699-706.
3. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol. 2004;15:524-537.
4. Neumann J, Ligtenberg G, Klein IH, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int. 2004;65:1568-1576.
5. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol. 2003;14:425-430.
6. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999;340:1321-1328.
7. Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol. 2004;15:2902-2907.
8. Vallbo AB, Hagbarth KE, Torebjork HE, Wallin BG. Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves. Physiol Rev. 1979;59:919-957.
9. Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol. 1984;247:F632-F636.
10. Snel YE, Brummer RJ, Bol E, Doerga ME, Zelissen PM, Zonderland ML, Boer P, Koomans HA, Koppeschaar HP. Direct assessment of extracellular water volume by the bromide-dilution method in growth hormone-deficient adults. Eur J Clin Invest. 1995;25:708-714.
11. Boer P, Sleumer JH, Spriensma M. Confirmation of the optimal pH for measuring renin activity in plasma. Clin Chem. 1985;31:149-150.
12. Beretta-Piccoli C, Weidmann P, Schiffl H, Cottier C, Reubi FC. Enhanced cardiovascular pressor reactivity to norepinephrine in mild renal parenchymal disease. Kidney Int. 1982;22:297-303.
13. Brecht HM, Ernst W, Koch KM. Plasma noradrenaline levels in regular haemodialysis patients. Proc Eur Dial Transplant Assoc. 1976;12:281-290.
14. Ishii M, Ikeda T, Takagi M, Sugimoto T, Atarashi K, Igari T, Uehara Y, Matsuoka H, Hirata Y, Kimura K, Takeda T, Murao S. Elevated plasma catecholamines in hypertensives with primary glomerular diseases. Hypertension. 1983;5:545-551.
15. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912-1918.
16. Ye S, Gamburd M, Mozayeni P, Koss M, Campese VM. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens. 1998;11:723-728.
17. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol. 2001;12:2427-2433.
18. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebocontrolled trial. J Am Coll Cardiol. 2003;41:1438-1444.
19. Vonend O, Marsalek P, Russ H, Wulkow R, Oberhauser V, Rump LC. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens. 2003;21:1709-1717.
20. Grassi G, Turri C, Seravalle G, Bertinieri G, Pierini A, Mancia G. Effects of chronic clonidine administration on sympathetic nerve traffic and baroreflex function in heart failure. Hypertension. 2001;38:286-291.
21. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens. 2006;24:243-256.
22. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cateliotti A, Stancanelli B, Malatino LS. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354-1359.
23. Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Cataliotti A, Malatino LS, on behalf of the CREED investigators. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension. 2002;40:41-46.